| Trial ID: | L5546 |
| Source ID: | NCT02475499
|
| Associated Drug: |
Dpp-4 Inhibitors
|
| Title: |
Incretin-based Drugs and Pancreatic Cancer
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: DPP-4 inhibitors|DRUG: GLP-1 analogs|DRUG: Sulfonylureas|DRUG: Biguanides|DRUG: Thiazolidinediones|DRUG: Alpha-glucosidase inhibitors|DRUG: Meglitinides
|
| Outcome Measures: |
Primary: Incident pancreatic cancer, Incident cases of pancreatic cancer recorded in a hospital database with the following ICD codes: ICD-9:157.0-157.9 ICD-10:C25.x, Patients were followed from the date of study cohort entry until hospitalization for incident pancreatic cancer, censoring, or for up to 79 months. |
|
| Sponsor/Collaborators: |
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES | Collaborators: Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
886172
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2014-03
|
| Completion Date: |
2015-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-03-14
|
| Locations: |
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, H3T1E2, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02475499
|
